Caliper Life Sciences - LabChip 3000
The LabChip 3000 is Caliper’s flagship enzymatic drug discovery system utilizing microfluidic technology for in vitro experiments.
The LabChip 3000 drug discovery system miniaturizes, integrates and automates enzymatic and cell-based assays. LabChip assays are separations-based, so the quality of results exceeds what is achievable in homogenous, well-based assays. High Z' values, few false positives, few false negatives and analytical quality reproducibility are the reasons cited for the increasing reliance on the LabChip 3000. No other screening system identifies weak enzyme inhibitors as reproducibly as the LabChip 3000.
Currently, 75% of the top 15 pharmaceutical companies are actively using Caliper systems as key tools in their screening efforts. Companies like Novartis, Johnson & Johnson, Sanofi-Aventis, Merck, Schering-Plough, Amgen, Lilly, Wyeth, and others are discovering the path to more productive screens. The most cited reason for using the Caliper system? Data quality. The number one application on the LabChip 3000 is kinase profiling, due to the high caliber of information that can be gained and the remarkably quick assay development time.
A variety of enzymatic assays can be performed on a single LabChip 3000 instrument. The assay menu for the LabChip 3000 includes:.
• Serine/Threonine Kinases
• Tyrosine Kinases
• Phosphatases
• Proteases
• Lipid-modifying Enzymes
• G-protein coupled receptors (GPCRs)
For more information visit:
http://www.caliperls.com/products/labchip-systems/labchip3000.htm...
